Wacker Chemie (WCH) Investor presentation summary

Financial performance and business overview

• Achieved €5.7bn in sales and €763m EBITDA in 2024, with a 13.3% EBITDA margin and 5.0% ROCE across 27 production sites and four business segments.

• Q1 2025 sales were €1,478m, with EBITDA of €127m and an 8.6% margin; net income was negative at -€3m, and net debt rose to €880m.

• FY 2025 guidance projects sales of €6.1–6.4bn and EBITDA of €700–900m, with net cash flow expected to be positive and CapEx significantly lower than the prior year.

• Chemicals, Silicones, Polymers, Biosolutions, and Polysilicon segments showed varied EBITDA margins, with Polysilicon leading at 20.4% in 2024.

Strategic targets and growth initiatives

• 2030 targets include sales above €10bn, EBITDA margin over 20%, and ROCE at twice the cost of capital.

• Focus on margin/mix over volume, with a goal to reduce CO2e emissions by 50% by 2030.

• CapEx program of €500–800m per year for 2025–26, prioritizing profitable growth, sustainability, and efficiency.

• Digitalization, automation, and regionalization initiatives aim for annual savings exceeding €100m, with specific cost and efficiency measures planned through 2026.

Segment highlights and market positioning

• Silicones: Positioned as a fully integrated specialty supplier, focusing on innovative solutions and sustainability-driven applications in construction, e-mobility, and electronics.

• Polymers: Capacity leader in VAE/DPP, driving innovation and sustainability trends such as "plastic to paper" and high construction standards.

• Biosolutions: Fast-growing biotech business with leading microbial manufacturing and CDMO services for advanced medicines, benefiting from health and well-being trends.

• Polysilicon: Maintains #1 position in high-end semiconductor materials, with strong barriers to entry and opportunities in solar driven by n-type technology demand.